U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06810804) titled 'A Phase IIa Study to Evaluate the Efficacy and Safety of NBQ72S' on Jan. 22.
Brief Summary: A phase IIa, single-arm, open-label study was conducted to evaluate the efficacy and safety of NBQ72S, in patients with leptomeningeal metastases from breast cancer. All patients will receive the study drug every 28 days until withdrawal from treatment.
Study Start Date: Feb. 28
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: NBQ72S
Patients will receive the study drug every 28 days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Nantong Bencao Quadriga Medical Technology Co. Ltd.
Published by HT Digital Conte...